Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 3/20 | 0.61 |
| ▸ | DPP4 | P27487 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 4/20 | 0.38 |
| ▸ | NPC1 | O15118 | 3/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | LTK | P29376 | 1/20 | 0.38 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.38 |
| ▸ | MST1R | Q04912 | 1/20 | 0.38 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.38 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.38 |
| ▸ | TDO2 | P48775 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6028964 | 0.80 | LTA4H (0.61) | LTA4HDPP4RAB9ANPC1ATM | |
| SCHEMBL3780733 | 0.80 | LTA4H (0.61) | LTA4HDPP4RAB9ANPC1ATM | |
| SCHEMBL5023959 | 0.80 | LTA4H (0.66) | LTA4HDPP4RAB9ANPC1LTK | |
| SCHEMBL4846964 | 0.80 | LTA4H (0.61) | LTA4HDPP4RAB9ANPC1ATM | |
| SCHEMBL477614 | 0.80 | LTA4H (0.61) | LTA4HDPP4RAB9ANPC1ATM | |
| SCHEMBL4848749 | 0.80 | LTA4H (0.61) | LTA4HDPP4RAB9ANPC1ATM | |
| SCHEMBL5018875 | 0.79 | LTA4H (0.60) | LTA4HDPP4RAB9ANPC1ATM | |
| Hydrochloric Acid SCHEMBL2463750 | 0.78 | LTA4H (0.59) | LTA4HDPP4RAB9ANPC1ATM | |
| SCHEMBL995326 | 0.78 | LTA4H (0.55) | LTA4HRAB9ANPC1ATMLTK | |
| SCHEMBL3906600 | 0.77 | LTA4H (0.57) | LTA4HDPP4RAB9ANPC1ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180305331-A1 | PYRIDONE DERIVATIVES AND THEIR USE AS KINASE INHIBITORS | SELVITA S.A. (PL) | 2018-10-25 | — | — | US | disclosed |
| US-7463400-B1 | Electrochromic display device | FUJI XEROX CO., LTD. (JP) | 2008-12-09 | — | — | US | disclosed |
| US-6284365-B1 | FOR CONTROLLING PHYSICAL PROPERTIES OF SURFACE AND INTERFACE OF SOLID ARTICLE SUCH AS WETTABILITY, ADHESIVE PROPERTY, SURFACE ENERGY, DISPERSABILITY, CHEMICAL RESISTANCE | FUJI XEROX CO., LTD. (JP) | 2001-09-04 | — | — | US | disclosed |
| US-5252574-A | Hypotensive agents, vision disorder | MERCK & CO., INC. (US) | 1993-10-12 | — | — | US | disclosed |
| US-5198438-A | ANGIOTENSIN II ANTAGONISTS INCORPORATING A SUBSTITUTED THIOPHENE OR FURAN | MERCK & CO., INC. (US) | 1993-03-30 | — | — | US | disclosed |
| US-5177074-A | Heterocyclic nitrogen compounds used to treat hypertension, cognitive dysfunction, anxiety or depression | MERCK & CO., INC. (US) | 1993-01-05 | — | — | US | disclosed |
| EP-0513979-A1 | Angiotensin II antagonists incorporating a substituted thiophene or furan | MERCK & CO. INC. (US) | 1992-11-19 | — | — | EP | disclosed |
| EP-0512675-A1 | Angiotensin II antagonists incorporating a substituted thiophene or furan | MERCK & CO. INC. (US) | 1992-11-11 | — | — | EP | disclosed |
| EP-0510812-A1 | Angiotensin II antagonists incorporating a substituted thiophene or furan | MERCK & CO. INC. (US) | 1992-10-28 | — | — | EP | disclosed |
| US-4426524-A | Heterocyclic substituted benzyl alcohol, insecticidal ester derivatives, and intermediates | FMC CORPORATION (US) | 1984-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180305331-A1 | PYRIDONE DERIVATIVES AND THEIR USE AS KINASE INHIBITORS | PDXK, PLK2, MAP4K2 | LTA4H 2772/4885DPP4 1992/4885RAB9A 3312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.